{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T19:50:43Z","timestamp":1771962643506,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute of Health","award":["R25GM133328"],"award-info":[{"award-number":["R25GM133328"]}]},{"name":"National Institute of Health","award":["R25GM133328"],"award-info":[{"award-number":["R25GM133328"]}]},{"name":"National Institute of Health","award":["R25GM133328"],"award-info":[{"award-number":["R25GM133328"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01805-0","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:52:45Z","timestamp":1759315965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic potential of Withaferin A in cancer-induced muscle and cardiac wasting"],"prefix":"10.1186","volume":"18","author":[{"given":"Mahavir","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh C.","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darini","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sham S.","family":"Kakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"1805_CR1","doi-asserted-by":"publisher","unstructured":"Saha S, Singh PK, Roy P, Kakar SS. Cardiac cachexia: unaddressed aspect in cancer patients. Cells. 2022;11(6). https:\/\/doi.org\/10.3390\/cells11060990","DOI":"10.3390\/cells11060990"},{"issue":"5","key":"1805_CR2","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3892\/or.2017.5542","volume":"37","author":"Y Belloum","year":"2017","unstructured":"Belloum Y, Rannou-Bekono F, Favier FB. Cancer-induced cardiac cachexia: pathogenesis and impact of physical activity (Review). Oncol Rep. 2017;37(5):2543\u201352. https:\/\/doi.org\/10.3892\/or.2017.5542","journal-title":"Oncol Rep"},{"issue":"5","key":"1805_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4103\/apjon.apjon-2126","volume":"8","author":"MR Baba","year":"2021","unstructured":"Baba MR, Buch SA. Revisiting cancer cachexia: pathogenesis, diagnosis, and current treatment approaches. Asia-Pacific J Oncol Nurs. 2021;8(5):508\u201318. https:\/\/doi.org\/10.4103\/apjon.apjon-2126","journal-title":"Asia-Pacific J Oncol Nurs"},{"key":"1805_CR4","doi-asserted-by":"publisher","unstructured":"Wiggs MP, Beaudry AG, Law ML. Cardiac remodeling in Cancer-Induced cachexia: functional, structural, and metabolic contributors. Cells. 2022;11(12). https:\/\/doi.org\/10.3390\/cells11121931","DOI":"10.3390\/cells11121931"},{"issue":"2","key":"1805_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11897-018-0378-8","volume":"15","author":"A Raina","year":"2018","unstructured":"Raina A, Meeran T. Right ventricular dysfunction and its contribution to morbidity and mortality in left ventricular heart failure. Curr Heart Fail Rep. 2018;15(2):94\u2013105. https:\/\/doi.org\/10.1007\/s11897-018-0378-8","journal-title":"Curr Heart Fail Rep"},{"issue":"5","key":"1805_CR6","doi-asserted-by":"publisher","first-page":"H1027","DOI":"10.1152\/ajpheart.00697.2018","volume":"316","author":"MV Singh","year":"2019","unstructured":"Singh MV, Cicha MZ, Nunez S, Meyerholz DK, Chapleau MW, Abboud FM. Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways. Am J Physiol Heart Circ Physiol. 2019;316(5):H1027\u201338. https:\/\/doi.org\/10.1152\/ajpheart.00697.2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1805_CR7","doi-asserted-by":"publisher","unstructured":"Vemuri V, Kratholm N, Nagarajan D, Cathey D, Abdelbaset-Ismail A, Tan Y, et al. Withaferin A as a potential therapeutic target for the treatment of angiotensin II-Induced cardiac cachexia. Cells. 2024;13(9). https:\/\/doi.org\/10.3390\/cells13090783","DOI":"10.3390\/cells13090783"},{"key":"1805_CR8","doi-asserted-by":"publisher","unstructured":"Kakar SS, Vemuri V, Ratajczak MZ. Withaferin A attenuates muscle cachexia induced by angiotensin II through regulating pathways activated by angiotensin II. Cells. 2025;14(4). https:\/\/doi.org\/10.3390\/cells14040244","DOI":"10.3390\/cells14040244"},{"issue":"16","key":"1805_CR9","doi-asserted-by":"publisher","first-page":"e15422","DOI":"10.14814\/phy2.15422","volume":"10","author":"M Singh","year":"2022","unstructured":"Singh M, Pushpakumar S, Zheng Y, Homme RP, Smolenkova I, Mokshagundam SPL, et al. Hydrogen sulfide mitigates skeletal muscle mitophagy-led tissue remodeling via epigenetic regulation of the gene writer and eraser function. Physiological Rep. 2022;10(16):e15422. https:\/\/doi.org\/10.14814\/phy2.15422","journal-title":"Physiological Rep"},{"issue":"4","key":"1805_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2174\/156800911795538057","volume":"11","author":"K Ino","year":"2011","unstructured":"Ino K, Shibata K, Yamamoto E, Kajiyama H, Nawa A, Mabuchi Y, et al. Role of the renin-angiotensin system in gynecologic cancers. Curr Cancer Drug Targets. 2011;11(4):405\u201311. https:\/\/doi.org\/10.2174\/156800911795538057","journal-title":"Curr Cancer Drug Targets"},{"key":"1805_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bcp.2018.03.008","volume":"151","author":"S Ishikane","year":"2018","unstructured":"Ishikane S, Takahashi-Yanaga F. The role of angiotensin II in cancer metastasis: potential of renin-angiotensin system Blockade as a treatment for cancer metastasis. Biochem Pharmacol. 2018;151:96\u2013103. https:\/\/doi.org\/10.1016\/j.bcp.2018.03.008","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1805_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.bjc.6602961","volume":"94","author":"K Ino","year":"2006","unstructured":"Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, et al. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer. 2006;94(4):552\u201360. https:\/\/doi.org\/10.1038\/sj.bjc.6602961","journal-title":"Br J Cancer"},{"issue":"3","key":"1805_CR13","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1002\/jcp.29163","volume":"235","author":"AK George","year":"2020","unstructured":"George AK, Singh M, Pushpakumar S, Homme RP, Hardin SJ, Tyagi SC. Dysbiotic 1-carbon metabolism in cardiac muscle remodeling. J Cell Physiol. 2020;235(3):2590\u20138. https:\/\/doi.org\/10.1002\/jcp.29163","journal-title":"J Cell Physiol"},{"issue":"40","key":"1805_CR14","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1093\/eurheartj\/eht424","volume":"40","author":"JD Groarke","year":"2019","unstructured":"Groarke JD, Cheng S, Jones LW, Moslehi J. Cancer cachexia: getting to the heart of the matter. Eur Heart J. 2019;40(40):e17\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/eht424","journal-title":"Eur Heart J"},{"issue":"9","key":"1805_CR15","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cell.2023.03.028","volume":"186","author":"M Ferrer","year":"2023","unstructured":"Ferrer M, Anthony TG, Ayres JS, Biffi G, Brown JC, Caan BJ, et al. Cachexia: A systemic consequence of progressive, unresolved disease. Cell. 2023;186(9):1824\u201345. https:\/\/doi.org\/10.1016\/j.cell.2023.03.028","journal-title":"Cell"},{"key":"1805_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.12.005","author":"E Wyart","year":"2025","unstructured":"Wyart E, Carr\u00e0 G, Angelino E, Penna F, Porporato PE. Systemic metabolic crosstalk as driver of cancer cachexia. Trends Endocrinol Metab. 2025. https:\/\/doi.org\/10.1016\/j.tem.2024.12.005","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"1805_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41416-022-01826-2","volume":"127","author":"J McGovern","year":"2022","unstructured":"McGovern J, Dolan RD, Skipworth RJ, Laird BJ, McMillan DC. Cancer cachexia: a nutritional or a systemic inflammatory syndrome? Br J Cancer. 2022;127(3):379\u201382. https:\/\/doi.org\/10.1038\/s41416-022-01826-2","journal-title":"Br J Cancer"},{"key":"1805_CR18","doi-asserted-by":"publisher","first-page":"745328","DOI":"10.3389\/fphys.2021.745328","volume":"12","author":"RP Homme","year":"2021","unstructured":"Homme RP, Zheng Y, Smolenkova I, Singh M, Tyagi SC. Remote Hind-Limb ischemia mechanism of preserved ejection fraction during heart failure. Front Physiol. 2021;12:745328. https:\/\/doi.org\/10.3389\/fphys.2021.745328","journal-title":"Front Physiol"},{"issue":"9","key":"1805_CR19","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/annonc\/mdx345","volume":"28","author":"B Laird","year":"2017","unstructured":"Laird B, Fallon M. Treating cancer cachexia: an evolving landscape. Annals Oncology: Official J Eur Soc Med Oncol. 2017;28(9):2055\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx345","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"1","key":"1805_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/apm.2018.08.04","volume":"8","author":"P Kasvis","year":"2019","unstructured":"Kasvis P, Vigano M, Vigano A. Health-related quality of life across cancer cachexia stages. Ann Palliat Med. 2019;8(1):33\u201342. https:\/\/doi.org\/10.21037\/apm.2018.08.04","journal-title":"Ann Palliat Med"},{"issue":"1","key":"1805_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13048-025-01636-z","volume":"18","author":"M Nair","year":"2025","unstructured":"Nair M, Samidurai A, Das A, Kakar SS, Kukreja RC. Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies. J Ovarian Res. 2025;18(1):72. https:\/\/doi.org\/10.1186\/s13048-025-01636-z","journal-title":"J Ovarian Res"},{"issue":"6","key":"1805_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10554-019-01590-0","volume":"35","author":"L Chen","year":"2019","unstructured":"Chen L, Huang J, Wu W, Ta S, Xie X. The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy. Int J Cardiovasc Imaging. 2019;35(6):1009\u201317. https:\/\/doi.org\/10.1007\/s10554-019-01590-0","journal-title":"Int J Cardiovasc Imaging"},{"issue":"8","key":"1805_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1292\/jvms.24-0004","volume":"86","author":"T Morita","year":"2024","unstructured":"Morita T, Uchida N, Kimura M. Effects of chemotherapy treatment with doxorubicin on right ventricular function in dogs. J Vet Med Sci. 2024;86(8):885\u201391. https:\/\/doi.org\/10.1292\/jvms.24-0004","journal-title":"J Vet Med Sci"},{"issue":"7","key":"1805_CR24","doi-asserted-by":"publisher","first-page":"e42265","DOI":"10.1371\/journal.pone.0042265","volume":"7","author":"MY Fong","year":"2012","unstructured":"Fong MY, Jin S, Rane M, Singh RK, Gupta R, Kakar SS. Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS ONE. 2012;7(7):e42265. https:\/\/doi.org\/10.1371\/journal.pone.0042265","journal-title":"PLoS ONE"},{"issue":"7","key":"1805_CR25","doi-asserted-by":"publisher","first-page":"e0236680","DOI":"10.1371\/journal.pone.0236680","volume":"15","author":"NQ Kelm","year":"2020","unstructured":"Kelm NQ, Straughn AR, Kakar SS. Withaferin A attenuates ovarian cancer-induced cardiac cachexia. PLoS ONE. 2020;15(7):e0236680. https:\/\/doi.org\/10.1371\/journal.pone.0236680","journal-title":"PLoS ONE"},{"issue":"1","key":"1805_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13048-019-0586-1","volume":"12","author":"AR Straughn","year":"2019","unstructured":"Straughn AR, Kakar SS. Withaferin A ameliorates ovarian cancer-induced cachexia and Proinflammatory signaling. J Ovarian Res. 2019;12(1):115. https:\/\/doi.org\/10.1186\/s13048-019-0586-1","journal-title":"J Ovarian Res"},{"key":"1805_CR27","doi-asserted-by":"publisher","first-page":"636498","DOI":"10.3389\/fcell.2021.636498","volume":"9","author":"AR Straughn","year":"2021","unstructured":"Straughn AR, Kelm NQ, Kakar SS. Withaferin A and ovarian cancer antagonistically regulate skeletal muscle mass. Front Cell Dev Biol. 2021;9:636498. https:\/\/doi.org\/10.3389\/fcell.2021.636498","journal-title":"Front Cell Dev Biol"},{"issue":"43","key":"1805_CR28","doi-asserted-by":"publisher","first-page":"74494","DOI":"10.18632\/oncotarget.20170","volume":"8","author":"SS Kakar","year":"2017","unstructured":"Kakar SS, Parte S, Carter K, Joshua IG, Worth C, Rameshwar P, et al. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget. 2017;8(43):74494\u2013505. https:\/\/doi.org\/10.18632\/oncotarget.20170","journal-title":"Oncotarget"},{"issue":"1","key":"1805_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13048-024-01519-9","volume":"17","author":"K Kumar","year":"2024","unstructured":"Kumar K, Bosch K, Vemuri V, Kratholm N, Rane M, Kakar SS. Withaferin A ameliorates ovarian cancer-induced renal damage through the regulation of expression of inflammatory cytokines. J Ovarian Res. 2024;17(1):199. https:\/\/doi.org\/10.1186\/s13048-024-01519-9","journal-title":"J Ovarian Res"},{"issue":"4","key":"1805_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.bbrc.2012.06.047","volume":"423","author":"SS Kakar","year":"2012","unstructured":"Kakar SS, Jala VR, Fong MY. Synergistic cytotoxic action of cisplatin and Withaferin A on ovarian cancer cell lines. Biochem Biophys Res Commun. 2012;423(4):819\u201325. https:\/\/doi.org\/10.1016\/j.bbrc.2012.06.047","journal-title":"Biochem Biophys Res Commun"},{"key":"1805_CR31","doi-asserted-by":"publisher","unstructured":"Kakar SS, Worth CA, Wang Z, Carter K, Ratajczak M, Gunjal P. DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. J Cancer Stem Cell Res. 2016;4. https:\/\/doi.org\/10.14343\/JCSCR.2016.4e1002","DOI":"10.14343\/JCSCR.2016.4e1002"},{"issue":"9","key":"1805_CR32","doi-asserted-by":"publisher","first-page":"e107596","DOI":"10.1371\/journal.pone.0107596","volume":"9","author":"SS Kakar","year":"2014","unstructured":"Kakar SS, Ratajczak MZ, Powell KS, Moghadamfalahi M, Miller DM, Batra SK, et al. Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells. PLoS ONE. 2014;9(9):e107596. https:\/\/doi.org\/10.1371\/journal.pone.0107596","journal-title":"PLoS ONE"},{"issue":"1","key":"1805_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13048-020-00684-x","volume":"13","author":"AR Straughn","year":"2020","unstructured":"Straughn AR, Kakar SS, Withaferin A. A potential therapeutic agent against COVID-19 infection. J Ovarian Res. 2020;13(1):79. https:\/\/doi.org\/10.1186\/s13048-020-00684-x","journal-title":"J Ovarian Res"},{"key":"1805_CR34","doi-asserted-by":"publisher","unstructured":"Bhullar SK, Dhalla NS. Angiotensin II-Induced signal transduction mechanisms for cardiac hypertrophy. Cells. 2022;11(21). https:\/\/doi.org\/10.3390\/cells11213336","DOI":"10.3390\/cells11213336"},{"issue":"6","key":"1805_CR35","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/hypertensionaha.112.198465","volume":"60","author":"A Yildirim","year":"2012","unstructured":"Yildirim A, Russell J, Yan LS, Senchenkova EY, Granger DN. Leukocyte-dependent responses of the microvasculature to chronic angiotensin II exposure. Hypertension. 2012;60(6):1503\u20139. https:\/\/doi.org\/10.1161\/hypertensionaha.112.198465","journal-title":"Hypertension"},{"issue":"6","key":"1805_CR36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1161\/hypertensionaha.111.172700","volume":"57","author":"M Kurdi","year":"2011","unstructured":"Kurdi M, Booz GW. New take on the role of angiotensin II in cardiac hypertrophy and fibrosis. Hypertension. 2011;57(6):1034\u20138. https:\/\/doi.org\/10.1161\/hypertensionaha.111.172700","journal-title":"Hypertension"},{"issue":"6","key":"1805_CR37","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3892\/ijo.15.6.1155","volume":"15","author":"MF Burbridge","year":"1999","unstructured":"Burbridge MF, Kraus-Berthier L, Naze M, Pierre A, Atassi G, Guilbaud N. Biological and Pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity. Int J Oncol. 1999;15(6):1155\u201362. https:\/\/doi.org\/10.3892\/ijo.15.6.1155","journal-title":"Int J Oncol"},{"issue":"2","key":"1805_CR38","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ygyno.2016.05.028","volume":"142","author":"L Hernandez","year":"2016","unstructured":"Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, et al. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol. 2016;142(2):332\u201340. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.028","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1805_CR39","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1038\/s41467-023-40639-6","volume":"14","author":"ZG Ma","year":"2023","unstructured":"Ma ZG, Yuan YP, Fan D, Zhang X, Teng T, Song P, et al. IRX2 regulates angiotensin II-induced cardiac fibrosis by transcriptionally activating EGR1 in male mice. Nat Commun. 2023;14(1):4967. https:\/\/doi.org\/10.1038\/s41467-023-40639-6","journal-title":"Nat Commun"},{"key":"1805_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pcad.2025.01.001","volume":"89","author":"A Sartorio","year":"2025","unstructured":"Sartorio A, Cristin L, Pont CD, Farzaneh-Far A, Romano S. Global longitudinal strain as an early marker of cardiac damage after cardiotoxic medications, a state-of-the-art review. Prog Cardiovasc Dis. 2025;89:92\u2013101. https:\/\/doi.org\/10.1016\/j.pcad.2025.01.001","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"1805_CR41","first-page":"1132","volume":"11","author":"TW Mudd Jr","year":"2021","unstructured":"Mudd TW Jr., Khalid M, Guddati AK. Cardiotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11(4):1132\u201347.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"1805_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.31083\/j.rcm2503087","volume":"25","author":"O Leiva","year":"2024","unstructured":"Leiva O, Beaty W, Soo S, Agarwal MA, Yang EH. Cancer Therapy-Associated pulmonary hypertension and right ventricular dysfunction: etiologies and prognostic implications. Rev Cardiovasc Med. 2024;25(3):87. https:\/\/doi.org\/10.31083\/j.rcm2503087","journal-title":"Rev Cardiovasc Med"},{"key":"1805_CR43","doi-asserted-by":"publisher","first-page":"609194","DOI":"10.1155\/2015\/609194","volume":"2015","author":"A Calleja","year":"2015","unstructured":"Calleja A, Poulin F, Khorolsky C, Shariat M, Bedard PL, Amir E, et al. Right ventricular dysfunction in patients experiencing cardiotoxicity during breast cancer therapy. J Oncol. 2015;2015:609194. https:\/\/doi.org\/10.1155\/2015\/609194","journal-title":"J Oncol"},{"issue":"4","key":"1805_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ejhf.1385","volume":"21","author":"K Keramida","year":"2019","unstructured":"Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail. 2019;21(4):529\u201335. https:\/\/doi.org\/10.1002\/ejhf.1385","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1805_CR45","doi-asserted-by":"publisher","first-page":"102919","DOI":"10.1016\/j.cpcardiol.2024.102919","volume":"50","author":"H Jain","year":"2025","unstructured":"Jain H, Ahmed M, Tariq MD, Jain J, Goyal A, Odat RM, et al. Right ventricular strain as a predictor of trastuzumab-induced chemotherapy-related cardiac dysfunction: A meta-analysis. Curr Probl Cardiol. 2025;50(1):102919. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102919","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"1805_CR46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/aln.0000000000001891","volume":"128","author":"GJ Crystal","year":"2018","unstructured":"Crystal GJ, Pagel PS. Right ventricular perfusion: physiology and clinical implications. Anesthesiology. 2018;128(1):202\u201318. https:\/\/doi.org\/10.1097\/aln.0000000000001891","journal-title":"Anesthesiology"},{"issue":"18","key":"1805_CR47","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.jacc.2013.07.021","volume":"62","author":"MR Mehra","year":"2013","unstructured":"Mehra MR. Fat, cachexia, and the right ventricle in heart failure: a web of complicity. J Am Coll Cardiol. 2013;62(18):1671\u20133. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1805_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","volume":"7","author":"T Aoyagi","year":"2015","unstructured":"Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7(4):17\u201329. https:\/\/doi.org\/10.4251\/wjgo.v7.i4.17","journal-title":"World J Gastrointest Oncol"},{"issue":"5","key":"1805_CR49","doi-asserted-by":"publisher","first-page":"C609","DOI":"10.1152\/ajpcell.00147.2018","volume":"315","author":"A Majumder","year":"2018","unstructured":"Majumder A, Singh M, Behera J, Theilen NT, George AK, Tyagi N, et al. Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and Endoplasmic reticulum stress injury. Am J Physiol Cell Physiol. 2018;315(5):C609\u201322. https:\/\/doi.org\/10.1152\/ajpcell.00147.2018","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01805-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01805-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01805-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:52:46Z","timestamp":1759315966000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01805-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1805"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01805-0","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"The author confirms that the work described has not been published before.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}